Abbott acquisition of Alere to proceed, but at reduced price

14 April 2017
mergers-acquisitions-big

More than a year after the original acquisition bid was announced, and months of acrimonious legal wrangling, USA-based Abbott (NYSE: ABT) is to proceed with the purchase of Alere (NYSE: ALR), but on revised terms.

Under the amended terms, Abbott will pay $51 per common share (versus the earlier $56) to acquire Alere, for a new expected equity value of around $5.3 billion, reduced from the originally expected equity value of about $5.8 billion.

Alere’s share price closed at $42.31 on Thursday, ahead of today’s formal joint announcement by Abbott and Alere.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical